Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The problem with math is GIGO.
The answer to this is very simple. Have a company present a drug or treatment that slows the decline or improves the functioning of AD patients that does not attack AD via amyloid.
So far the FDA hasn't seen such a drug or treatment.
I wonder what company will be the first to do that?
Can anybody explain what is going on w/the SP today ? Why down? What is being said/done to cause what we are seeing? AGAIN...???We should at least be stable-flat...IMO.
Are the AHs still trying to scare people? who posts as frequently as these MFrs unless they have an agenda?
Approval of trofenide will NOT delay the approval of Anavex’s blarcamesine according to FDA rules.
GOD bless,
Orphan drugs get 7 years of exclusivity and typical new drugs get only 5 years. Exclusivity does not prevent marketing of a new chemical entity for the orphan disease but rather a generic with the same active moiety. So the FDA's action on trofinetide has no bearing on the regulatory approval of blarcamesine. Though regulatory exclusivity is 7 years for Rett (and other orphan diseases), for AD or PDD, it would only be 5 years. However, patents listed in the Orange book associated with the approval of a drug can extend the commercial exclusivity (commercial exclusivity is the longer of regulatory and legal exclusivity). Patents not listed in the Orange book can usually be litigated away so seldom prolong the exclusivity.
Wow...at the center of the cabal...
why hurry ?
Time is your friend and you will have a lot of 'friend'
Exclusivity can prohibit approval of competitor drugs.
That's how I read this:
1 million or two million shares? George II?
Ought to soon be time for the MM long dog-whistle.
Expecting to reload many shares between now and EOD....
You can find the cc on anavex.com...
It's been previously posted several times.
I WISH Iowned a TARDIS rental franchise.
Do you have a link to the transcript of him saying this?
The plot thickens. lol
yes, just checked and you are right about the weighting. It is equal-weighted with quarterly rebalancing on the 3rd Friday of the quarter ending month. It was 9.18 on Friday Sept 23 and 8.45 Friday Dec 23
No!!!
The exclusivity applies only to the sale of the approved drug ( in your case trofenitide)
See below
How long does an exclusivity period last?
It depends on what type of exclusivity is at issue.
Orphan Drug Exclusivity (ODE) – 7 years
New Chemical Entity Exclusivity (NCE) – 5 years
Generating Antibiotic Incentives Now (GAIN) Exclusivity– 5 years added to certain exclusivities
New Clinical Investigation Exclusivity – 3 years
Pediatric Exclusivity (PED) – 6 months added to existing Patents/Exclusivity
Patent Challenge (PC) – 180 days (this exclusivity is for ANDAs only)
Competitive Generic Therapy (CGT) - 180 days (this exclusivity is for ANDAs only)
See 21 C.F.R. 314.108, 316.31, 316.34 and sections 505A, 505E, 505(j)(5)(B)(iv), and Section 505(j)(5)(B)(v) of the FD&C Act.
https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity
Trofinetide's exclusivity has nothing to due with Anavex's blarcamesine.
GOD bless,
According to George.....
Pantheon and Syntagon combined give Anavex the production process control and capacity to produce Blarcamesine for commercialization and worldwide distribution and sales.
Manufacturing certainly. Distribution? Maybe contract with McKesson for that.
Pantheon and Syntagon could also be contracts.
NO need for "partners" to take some ouf our equity returns.
Sorry, Doc, missed your comment. I believe XBI is equal weighted. IBB is proportionally weighted.
FWIW - At 10:00am, he said he was "already making money."
Do you sell some shares short? I don't recall you posting about that trade.
That is why Rett will be first.... much smaller population.
Pantheon and Syntagon combined give Anavex the production process control and capacity to produce Blarcamesine for commercialization and worldwide distribution and sales.
https://patheon.com/
https://www.syntegon.com/company
Good luck and GOD bless,
To summarize your long answer, and the unnecessary lesson on how index funds work, you do not know which funds State Street holds AVXL in. Neither do any of the others who proclaim that State Street does not actively choose to invest in AVXL.
By the way, AVXL’s share price/market cap has not significantly changed sine the prior quarter so State Street’s 40% increase in AVXL shares cannot be explained by rebalancing in an index fund like the Russell.
If Orphan Drug status confers exclusivity, would trofinetide approval block blarcamesine approval/use for Rett? (I'm asking this out of confessed total ignorance.)
Isn't the manufacturing partner part of the NDA?
I though that the FDA wants to review the supply chain as well as the science? IF that is the case, partnership would likely be before, not after, NDA.
Which means shorts could wake up any day to a 300% gain in the stock price and obliteration of their positions?
TGD might be in bed with LPC, I won't be surprised if there is offshore account in cayman, accountant is crafty in this matter. 4th agreement with LPC, not sure any other shady bio has done so many agreements with LPC vulture.
So then provide a link to proof that State Street holds AVXL only in index funds. What fund or funds does State Street hold AVXL in? Otherwise you and others assume, without knowing, that no shares are held in managed funds.
Is there someone guaranteeing that Roche will by the stock? I must have missed that.
I recall seeing that there is a poster that says Roche is interested in Anavex. I suspect there are a lot of BP that follow Anavex closely and are interested in it. That interest will increase considerably once an NDA is filed and get even stronger once the NDA is approved. Will it be Roche or some other BP?
As you say, it is wait and see for now.
Doc, I think once the trofinetide trial went OLE they were able to remove the meds being taken for constipation and alter the diet and from what I have read its modified the original side effects and allowed for increased improvements as time on treatment been extended. So far Acadia hasn't given guidance as to their drug pricing but so happy that in all likelihood patients will have an approved option this spring. Also interested to see if they allow scripts down to 2 years as the OLE has allowed. Hopefully 273 can be used on top of this somewhere down the line. GLTA
https://medicine.wustl.edu/news/pediatric-clinic-for-rett-syndrome-draws-patients-for-multispecialty-care-clinical-trials/
Do you understand what balancing and rebalancing means. rebalancing would not and does not result in 1 40% increase in shares due to rebalancing of an index fund.
GOD bless,
No I like to know the narrative being pushed, as the message is there and not on what is being said.
For those that are influenced by the actual words, yes I recommend the ignore button too.
Sure. Index funds holdings increase or decrease based on changes in the underlying index they track (in our case it’s the Russell 2000). As you may know, an index fund is a type of passive investment vehicle that aims to replicate the performance of a specific market index, such as the S&P 500 or the NASDAQ. In our case it’s the Russell 2000. The funds’ holdings are designed to reflect the composition of the Russell 2000 index, with the goal of matching its performance as closely as possible.
If AVXL rises, and its market capitalization grows, the weight of AVXL in the tracking funds will increase, and the funds will typically purchase more of the stock to maintain the desired weighting in the Russell 2000 index. On the other hand, if AVXL drops, its weight in the index will decrease, and the tracking funds will sell some of their holdings in the stock.
And of course as more AVXL shares are acquired by index funds, the number of shares available for immediate trading decreases, hence liquidity is reduced. Biotech funds typically want to buy in size, so if liquidity resulting from more shares being bought by index funds is lowered, it makes it harder for institutional investors to acquire a significant number of shares without significantly moving the market. That is why I argue that more shares held by index funds is actually bad.
While it’s not clear exactly which State Street fund owns AVXL, the percentage increase in its holdings of AVXL strongly suggests the fund is an index fund that tracks the Russell 2000.
Shareholders who cheer when an index fund increases its holdings of AVXL because they see it as a sign of positive sentiment are assuming something that is not true. Again, index funds are tracking funds that buy and sell according to the information above. The time to cheer is when you see the likes of biotech funds like Biotechnology Value Fund, Janus Life Sciences Fund or Perceptive Life Sciences Fund starting positions. Sadly, but not surprisingly, there are no biotech funds holding AVXL.
Yea...no, don't think so.
All shareholders through index funds and ETFs. Google State Street. The first line of the results says ETFs.
These companies are not buying because they analyzed Anavex and decided to buy. These companies have to buy (or sell) Anavex and other biotechs to include at the proper weighting in the funds. This idea is not debatable or controversial except for those who can't handle the truth.
This has been explained many times across may boards and WGT crowd either doesn't understand how these firms work or doesn't want to know the truth.
State Street rebalances the XBI quarterly so big shifts in ownership are not uncommon
Please explain how supposedly a State Street index fund suddenly increased its position by 40%. Did investors add 40% into the fund or did State Street drastically increase AVXL’s weighting? Also, can you identify what specific fund State Street holds its AVXL shares in, to prove that it is, in fact, an index fund as you claim?
It's that 5% of value that prevents placing on "ignore". LOL
DR.M have a MBA i don't think he is stupid to sign a deal that not benefit the company.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
boi - If long investors don't have special access to data or the schedule of upcoming company actions, you can be damn sure the shorts don't either. Everything they're spewing is conjured up to support a negative self-serving agenda a.k.a. they're lying.
My ignore list is long and keeps growing.
I can think of one reason.
Anyone wonder why AVXL is still registered and incorporated in Nevada?
Anyone know of a real = non-grift firm that isn't incorporated in Delaware?
That's where corporations have the most protection
They don't want their corporate documents stored in a garage.
Bill
The LPC agreement is more like a "Put" agreement whereby LPC must purchase the shares per the formula up to agreed amounts. The formula mitigates the risk to LPC and is common in equity financing agreements. The terms of the price calculation are fair.
The Cantor agreement had no obligation of Cantor to buy, but simply for Cantor to act as an intermediary or placement agent for a 3% fee with discretion for Cantor to not act, but to instead act on good faith based on market conditions.
Yes, and they’re all index funds. When index funds increase their holdings, the stock becomes less liquid, which increases volatility.
We don’t need more index fund holdings. We need biotech funds buying in. Sadly, we have none.
TYFNP!
sumbuysumsell[quote]Food for thought. There's power in staying quiet.
[/quote]
YUP, (for example) The FDA has been completely wrong on the whole Amyloid Plaque thing for at least 100 years now???HUH...wonder why??? SILENCE WORKS...(along w/BP and who knows about the herd??). IMO, Massive $$$$ is part of the answer.
Blackrock, State Street and VanGuard are all LARGE shareholders in Anavex Life Sciences stock AVXL.
Good luck and GOD bless,
All market participants whether they will admit it or not are part of a cabal.
Followers
|
1075
|
Posters
|
|
Posts (Today)
|
105
|
Posts (Total)
|
463338
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |